Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: J Pain. 2017 Jun 29;18(11):1333–1345. doi: 10.1016/j.jpain.2017.06.005

Figure 4. Ablation of central terminals of TRPV1-expressing afferents attenuates spontaneous and bite-evoked pain during masseter inflammation.

Figure 4

A. Time line of experiment. RTX (50 ng in 0.5 µl PBS per side) or vehicle (0.5 µl per side) was microinjected bilaterally into trigeminal nucleus caudalis (Vc) two weeks prior to the start of behavioral assessments. CFA (20 µl per side) was bilaterally injected into the masseter muscles. MGS and bite force were evaluated from same groups of animals 1, 3, and 6 days after CFA injections.

B–C. Averaged MGS scores (B) and normalized bite force (C) before and after masseter injection of Veh or CFA in Vc-Veh- or Vc-RTX-injected mice. ***p<0.001 (Vc-Veh/CFA vs Vc-RTX/CFA); post-hoc analysis following two-way ANOVA. Numbers in parenthesis represent the number of mice.

D. Representative immunohistochemical staining of TRPV1 in Vc from Vc-RTX mice or Vc-Veh mice. Scale bar, 100 µm.